Vidac Pharma

Company Overview

Snapshot

Founded in January 2012 by Professor Max Herzberg, Vidac Pharma operates with 1–10 employees. The company has raised $9 million across two funding rounds from four investors. Vidac Pharma became publicly listed on the Hamburg Stock Exchange in March 2023.

Business overview

Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for oncologic and dermatologic diseases. The company's core technology targets the VDAC/HK2 system in malignant cells, aiming to induce selective apoptosis of cancer cells while preserving healthy tissue. Vidac Pharma's lead drug, VDA-1102, has completed a Phase 2b clinical trial for actinic keratosis and is in a Phase 2a trial for CTCL. Additionally, the company is developing VDA-1275, a potent small-molecule new chemical entity for systemic treatment of solid tumors, operating within the Health Tech & Life Sciences sector.

Strategic signal

Vidac Pharma continues to strengthen its intellectual property portfolio, as evidenced by the U.S. patent grant in September 2024 for the mode of action underlying its oncology drug candidates. This patent provides broad protection and validates the company's innovative approach to cancer treatment, signaling robust progress in its drug development pipeline and potential for future market exclusivity.

Company Intelligence Q&A

When did Vidac Pharma become a public company?

Vidac Pharma became publicly listed on the Hamburg Stock Exchange in March 2023.

What was a significant funding event for Vidac Pharma?

In June 2016, Vidac Pharma received funding from investors including.

What recent patent approval did Vidac Pharma receive?

In September 2024, the U.S. granted Vidac Pharma a patent offering broad protection of the mode of action underlying its oncology drug candidates.

What is the status of Vidac Pharma's lead drug, VDA-1102?

In January 2024, Vidac Pharma reported positive interim Phase 2a data for VDA-1102 in the orphan disease cutaneous T-cell lymphoma (CTCL). The company also secured approval in March 2024 for the next phase of clinical study for VDA-1102 in CTCL.

What progress has Vidac Pharma made with its VDA-1275 cancer drug candidate?

In March 2024, Vidac Pharma received a Japanese Patent Office Notice of Allowance for its VDA-1275 cancer drug candidate. In February 2024, the company presented high efficacy for VDA-1275 in multiple solid tumor models and synergy with standard-of-care treatment in liver cancer organoids.